Auto-focusing spectacles

Article

A trial of electronic spectacles with dynamic focusing lenses has begun enrolling its first wearers, according to an announcement from the spectacles' manufacturer, PixelOptics Inc.

A trial of electronic spectacles with dynamic focusing lenses has begun enrolling its first wearers, according to an announcement from the spectacles' manufacturer, PixelOptics Inc.

The spectacles use a composite of electricity, chemistry and optic technology to focus faster than a blinking eye, providing clear near, intermediate and distance vision. As such, these "electro-active" spectacles would be suitable non-surgical correction for presbyopia. The limited and controlled trials will run throughout the year, ahead of the lenses" anticipated market launch in 2010. PixelOptics claims that the lenses will not differ significantly from traditional lenses in terms of cosmetic factors (such as style, thickness and transparency) and weight. The lenses are lineless and provide a wider and less compromised field of vision than is available with current lenses.

PixelOptics, which concentrates on developing these "composite" lenses, is also developing static focus lenses. It launched its first static composite lens, the atLast! Enhanced Multifocal, which provides enhanced intermediate vision to bifocal and trifocal spectacle wearers, in October 2008. The dynamic electronic lenses will be showcased for the first time at the International Vision Expo East in New York, March 27–29, 2009.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.